To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis

Condition:   Moderate to Severe Chronic Plaque Psoriasis Interventions:   Biological: CT-P17;   Biological: EU-approved Humira Sponsor:   Celltrion Not yet recruiting

Source: ClinicalTrials.gov - August 10, 2022 Category: Research Source Type: clinical trials